Celerion invests in its site in Fehraltdorf

(CONNECT) Celerion is expanding its bioanalytical laboratory at the company’s Swiss location in Fehraltdorf near to Zurich. As detailed in a statement issued by the company from Lincoln in the US State of Nebraska, this investment will strengthen Celerion’s ability to meet the growing worldwide demand for bioanalytical services, in addition to supporting rapid study execution and providing access to specialized scientific expertise across complex drug development programs. The plans involve targeted investments in cutting-edge instrumentation and specialized scientific talent.

“This expansion reflects both the growth of the bioanalytical market and the increasing demand we are seeing from our clients worldwide”, as Chad Briscoe, Executive Vice President of Global Bioanalytical Services at Celerion, explains in the statement. Celerion’s Swiss laboratory is integrated with the clinical research units in the USA and the UK, which is said to facilitate efficient sample management and the rapid delivery of high-quality data.

“As therapeutic modalities continue to evolve, our clients need bioanalytical partners that can scale alongside increasingly complex development programs”, comments Susan Thornton, who founded Celerion in 2010 and has been leading the company as CEO since then. "This investment ensures we remain well-positioned to deliver the expertise, quality, and responsiveness that help accelerate the development of new medicines”. ce/mm